固本抑瘤Ⅱ号及其拆方对A<sub>549</sub>抑瘤及与化疗联合用药的实验研究

张甘霖; 李萍; 王笑民; 唐勇; 刘欣; 盛巡

doi:10.13422/j.cnki.syfjx.2007.01.015

您当前的位置：

首页 >

文章列表页 >

固本抑瘤Ⅱ号及其拆方对A₅₄₉抑瘤及与化疗联合用药的实验研究

更新时间：2024-09-23

- 固本抑瘤Ⅱ号及其拆方对A₅₄₉抑瘤及与化疗联合用药的实验研究
- In Vitro Studies of Gubenyiliu Prescription Ⅱ and Its Functional Compositions on A₅₄₉ Lung Carcinoma Cell and Synergistic Action with Chemotherapy
- 中国实验方剂学杂志 2007年第1期页码：35-38
- 作者机构：
  
  1.   北京市中医研究所
  2.   首都医科大学附属北京中医医院肿瘤科
  3.   北京市中医研究所北京100010
  4.   北京中医药大学中药学教研室
  5.   北京100029
- 作者简介：
- 基金信息：
  
  北京市科委资助（H010910190119）
- DOI：10.13422/j.cnki.syfjx.2007.01.015
  中图分类号： R285.5
- 纸质出版日期：2007
- 稿件说明：
移动端阅览
[1]张甘霖,李萍,王笑民,唐勇,刘欣,盛巡.固本抑瘤Ⅱ号及其拆方对A_(549)抑瘤及与化疗联合用药的实验研究[J].中国实验方剂学杂志,2007(01):35-38.

ZHANG Gan-lin~. In Vitro Studies of Gubenyiliu Prescription Ⅱ and Its Functional Compositions on A₅₄₉ Lung Carcinoma Cell and Synergistic Action with Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2007, (1): 35-38.
[1]张甘霖,李萍,王笑民,唐勇,刘欣,盛巡.固本抑瘤Ⅱ号及其拆方对A_(549)抑瘤及与化疗联合用药的实验研究[J].中国实验方剂学杂志,2007(01):35-38. DOI： 10.13422/j.cnki.syfjx.2007.01.015.

ZHANG Gan-lin~. In Vitro Studies of Gubenyiliu Prescription Ⅱ and Its Functional Compositions on A₅₄₉ Lung Carcinoma Cell and Synergistic Action with Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2007, (1): 35-38. DOI： 10.13422/j.cnki.syfjx.2007.01.015.

摘要

目的:探讨益气活血中药固本抑瘤Ⅱ号（全方）和各拆方组药物对A549肺癌细胞生长的影响及与化疗药物顺铂（DDP）联合应用的效果。方法:固本抑瘤Ⅱ号全方和根据功效拆分的益气组、行气活血组、培补肝肾组、散结消组药物

分别制备水提物。采用MTT法检测各组药物对A549细胞生长的影响及与DDP联合作用的效果。结果:单独应用全方和行气活血组水提物对A549细胞生长表现为抑制作用

IC50分别为33.21 mg生药/mL和9.55 mg生药/mL;与DDP合用表现为增效作用

增效倍数分别为1.23和1.77

合并指数为1.05和0.83

表现出协同和相加作用。结论:固本抑瘤Ⅱ号在体外实验中能够抑制A549细胞生长

与DDP合用有一定的化疗增效作用;行气活血组药物也具有抑瘤和增效作用

且作用与全方接近。提示行气活血组中药为体外实验中全方抗肿瘤作用及化疗增效作用的有效组分。

Abstract

Objective:To study the effect of Gubenyiliu Prescription Ⅱ（Prescription Ⅱ

PⅡ） and its functional groups on A

549

lung carcinoma cell’s growth and combinative effect with diamminedichloroplatinum（DDP）.Methods:According to its functional composition

Prescription Ⅱ was divided into four groups:Reforcing vital energy group（VE）、Promoting qi to activate blood group（QB）、Cultivating kidney and liver group（KL）and Eliminating stagnation and removing lump group（SL）.Their aqueous extracts were prepared respectively.MTT assay was used for A

549

growth and combinative effect with DDP.Results:Both Prescription Ⅱ and QB group showed depressive effect on A

549

growth.The IC

was 33.21 mg crude drug/mL and 9.55 mg crude drug/mL respectively.Both of them had synergistic action with DDP

the multiple was 1.23 and 1.77

complicating index was 1.05 and 0.83 dccordingly.Conclusion:PⅡ can inhibit A

549

grow

and it has synergistic action with DDP to some extent.Among the functional groups

QB group has the similar effects with PⅡ.It indicates that herbs in QB group play the main active effect against tumour and synergetic action in the whole prescription.

关键词

Keywords

references

浏览量

187

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

固本抑瘤Ⅱ号及其拆方对A抑瘤及与化疗联合用药的实验研究

固本抑瘤Ⅱ号及其拆方对A549抑瘤及与化疗联合用药的实验研究

In Vitro Studies of Gubenyiliu Prescription Ⅱ and Its Functional Compositions on A549 Lung Carcinoma Cell and Synergistic Action with Chemotherapy

DOI：10.13422/j.cnki.syfjx.2007.01.015

摘要

Abstract

关键词

Keywords

references

固本抑瘤Ⅱ号及其拆方对A₅₄₉抑瘤及与化疗联合用药的实验研究

In Vitro Studies of Gubenyiliu Prescription Ⅱ and Its Functional Compositions on A₅₄₉ Lung Carcinoma Cell and Synergistic Action with Chemotherapy